Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Clin Cancer Res. 2012 Aug 2;18(19):5412–5426. doi: 10.1158/1078-0432.CCR-12-1780

Fig. 2. Positive hits from RNAi screening.

Fig. 2

(A) The primary RNAi screen was carried out in the HCT116 cell line with 1 siRNA sequence per target to functionally assess 84 candidate genes from key pathways. A positive ‘hit’ was defined by 2-way ANOVA as a significant (P<0.05) increase in relative toxicity (cell death/cell viability) with siRNA alone or siRNA combined with drug. (B) A secondary RNAi screen used an additional 3 siRNA sequences per target. A positive hit was classified as a significant increase in relative toxicity alone or combined with drug with ≥2 additional siRNA sequences. (C) A tertiary RNAi screen used the optimum chemo-sensitizing siRNA from the previous screens and incorporated a panel of 6 independent CRC cell lines. A positive hit was classified as a significant increase in relative toxicity alone or combined with drug in ≥3 cell lines. Results are given as mean values ± SEM of triplicate measurements. *P<0.05; **P<0.01; ***P<0.001. SC=siRNA control; si=targeted siRNA; SOL=solvent control.